We aimed to estimate the association of prophylactic antihemorrhagic medication use during dilation and evacuation (D&E) with operative hemorrhage and estimated blood loss (EBL). Records for all pregnant patients between 14 and less than 22 weeks of gestation who had a D&E procedure from January 2012 to December 2019 were retrospectively reviewed. Prophylactic antihemorrhagic medication use was defined as receiving vasoconstrictors, uterotonics, or both before identification of hemorrhage during a D&E procedure. Overall, 147 D&E procedures were completed at a mean of 16.4 (±2.2) weeks of gestation. Prophylactic medications were used in 72.1% (n=106) of D&E procedures. Prophylactic medication use was associated with lower operative hemorrhage (21.7% vs 51.2%, P<.01) and lower EBL (336.9 mL vs 551.3 mL, P<.01).

我们的目的是估计扩张和疏散 (D&E) 期间预防性抗出血药物的使用与手术出血和估计失血量 (EBL) 的关联。对 2012 年 1 月至 2019 年 12 月期间接受过 D&E 手术的所有妊娠 14 周至不到 22 周的孕妇的记录进行了回顾性审查。预防性抗出血药物的使用被定义为在 D&E 过程中识别出血之前接受血管收缩剂、子宫收缩剂或两者。总体而言，在平均妊娠 16.4 (±2.2) 周时完成了 147 次 D&E 手术。72.1% (n=106) 的 D&E 程序使用了预防性药物。预防性用药与较低的手术出血率 (21.7% vs 51.2%, P <.01) 和较低的 EBL (336.9 mL vs 551.P <.01)。